Approved Use: TAVNEOS® is a prescription medicine that is used with other medicines (such as glucocorticoids) to treat adults with severe
Read moreApproved Use: TAVNEOS® is a prescription medicine that is used with other medicines (such as glucocorticoids) to treat adults with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA], formerly known as Wegener’s granulomatosis, and microscopic polyangiitis [MPA]). It is not known if TAVNEOS is safe and effective in children under the age of 18.
Read lessThe link you have selected will take you away from the TAVNEOS® (avacopan) website to one that is not owned or controlled by ChemoCentryx. ChemoCentryx accepts no responsibility for the content of linked sites.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click “OK” if you are a healthcare professional.
Based on your location, you are being redirected to the website of our licensee Vifor Fresenius Medical Care Renal Pharma Ltd. CCXI does not have responsibility for, or control of, the contents, availability, operation, or performance of the website.

Time to fill is 7 days or less for most patients, regardless of insurance approval*

94% of insured patients, regardless of formulary coverage, were approved for TAVNEOS®†

TAVNEOS® Connect services are available for adult patients whose diagnosis is aligned with the FDA-approved indication for TAVNEOS®. Additional eligibility criteria and other terms and conditions apply.
Terms, conditions, and program maximums apply. Other restrictions may apply. This program is not open to patients receiving prescription reimbursement under any federal-, state-, or government-funded healthcare program, or for cash patients. This is not insurance or a guarantee of payment. No cash value. Void were prohibited by law.
*Based on Patient Enrollment forms from October 2021 through April 2025.
†Based on Patient Enrollment forms from October 2021 through December 2024.
‡Eligibility criteria and program maximums apply. See www.tavneos.com/copay for full Terms and Conditions.
Patients who are uninsured or are unable to afford their medication may be eligible to receive TAVNEOS® through Amgen’s nonprofit patient assistance program. Patients will need to complete a Patient Assistance Program application, meet certain eligibility criteria, and be screened for support.
Once you and your doctor decide if TAVNEOS® is right for you, join nephrologist Dr. Dia Waguespack as she discusses how you can access TAVNEOS® in just 3 steps and how Amgen can help support you throughout your treatment journey.
For any questions, call the TAVNEOS® Team at 1-833-TAVNEOS
(1-833-828-6367),
Monday through Friday from 8 to 8 ET
For any questions, call the TAVNEOS® Team at 1-833-TAVNEOS
(1-833-828-6367),
Monday through Friday from 8 to 8 ET
TAVNEOS can cause serious side effects, including:
Your healthcare provider will do blood tests to check how well your liver is working before starting and during your treatment with TAVNEOS.
Tell your healthcare provider about all the other medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. TAVNEOS and certain other medicines may affect each other and cause side effects. Keep a list of the medicines you take and show it to your healthcare provider and pharmacist.
The most common side effects of TAVNEOS include:
TAVNEOS is a prescription medicine that is used with other medicines (such as glucocorticoids) to treat adults with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA], formerly known as Wegener’s granulomatosis, and microscopic polyangiitis [MPA]).
These are not all the possible side effects of TAVNEOS. Call your doctor for medical advice about side effects. Please see the Full Prescribing Information and Medication Guide for further details.
TAVNEOS is available as a 10 mg capsule.
You are encouraged to report negative side effects to Amgen at 1-833-828-6367 or to the FDA by visiting www.fda.gov/medwatch or calling 1-800-332-1088.
IMPORTANT SAFETY INFORMATION What is the most important information I should know about TAVNEOS? TAVNEOS can cause serious side effects, including: Liver problems. People taking TAVNEOS may have serious liver problems. Call your healthcare provider right away if you have unexplained symptoms such as: